Table 3 Features of MG clinical improvement in new-onset MG patients after COVID-19 outbreak
From: The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study
Variables | MG Clinical Improvement | P value | |
|---|---|---|---|
|  | NO (n = 71) | YES (n = 123) |  |
Gender, female, n (%) | 33 (46.48) | 72 (58.54) | 0.104 |
BMI (mean ± SD) | 22.01 ± 3.61 | 22.64 ± 3.83 | 0.511 |
Smoking, n (%) | 14 (19.72) | 16 (13.01) | 0.213 |
Vaccination, ≥ 1, n (%) | 64 (90.14) | 107 (86.99) | 0.513 |
Infection rate, n (%) | 68 (95.77) | 117 (95.12) | 0.835 |
Age at onset (y), median (IQR) | 49 (35, 60) | 36 (20, 52) | 0.001* |
MG duration (w), median (IQR) | 14 (6, 32) | 15 (5, 32) | 0.969 |
Season of onset, Winter and Spring, n (%) | 40 (56.34) | 68 (55.28) | 0.887 |
MGFA, | Â | Â | 0.002* |
 < III, n (%) | 64 (90.14) | 87 (70.73) |  |
 ≥ III, n (%) | 7 (9.86) | 36 (29.27) |  |
Clinical phenotype | Â | Â | 0.019* |
 Ocular, n (%) | 47 (66.20) | 60 (48.78) |  |
 Generalized, n (%) | 24 (33.80) | 63 (51.22) |  |
Affect bulbar or respiratory muscles, n (%) | 8 (11.26) | 37 (30.08) | 0.003* |
Affect limb muscles, n (%) | 16 (22.54) | 26 (21.14) | 0.820 |
Antibody status (missed 3) | Â | Â | 0.220 |
 AChRab +, n (%) | 50 (72.46) | 87 (71.31) |  |
 MuSKab +, n (%) | 3 (4.35) | 13 (10.66) |  |
 Seronegative, n (%) | 13 (18.84) | 19 (15.57) |  |
Abnormal thymus (missed 1), n (%) | 27 (38.57) | 42 (34.15) | 0.380 |
RNS + (missed 13), n (%) | 30 (44.78) | 58 (50.88) | 0.428 |
MG treatment | Â | Â | Â |
 Pyridostigmine, n (%) | 65 (91.55) | 122 (99.19) | 0.019* |
 Prednisolone, n (%) | 47 (66.20) | 89 (72.36) | 0.367 |
 Immunosuppressants, n (%) | 9 (12.68) | 38 (30.89) | 0.004* |
 AZA, n (%) | 1 (1.41) | 5 (4.07) | 0.549 |
 MMF, n (%) | 2 (2.82) | 8 (6.50) | 0.434 |
Tacrolimus, n (%) | 6 (8.45) | 25 (20.33) | 0.030* |
Baseline MG-ADL, median (IQR) | 3 (3, 3) | 5 (3, 6) |  < 0.001* |